Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CONTROLLED RELEASE DRUG FORMULATIONS WITH INDIRECT THERAPEUTIC EFFECT, POTENTIAL FOR IRREVERISIBILE TOXICITY, SHOULD BE SUPPORTED BY CLINICALS

Executive Summary

Clinical studies for controlled release formulations are preferable in at least four situations, according to preliminary guidelines released by FDA on Sept. 5. The guidelines were issued as a report on the September 1985 workshop on controlled release dosage forms sponsored by FDA, the Drug Information Association, the Academy of Pharmaceutical Sciences and the American Society for Clinical Pharmacology & Therapeutics. Authors of the guidelines include FDA Biopharmaceutics Div. Director Jerome Skelly, PhD, and Office of Drug Research & Review Director Robert Temple, MD. Describing the purpose of the report, the authors state that it is "an initial attempt to develop guidelines for the design, conduction, and evaluation of studies of controlled release pharmaceutical dosage forms. No attempt has been made to achieve completeness, and it has been written with the recognition that it can and should be improved." The need for clinical trial information on a controlled release formulation is "a fundamental question in developing a controlled release product," the report notes. According to the guidelines, clinical studies will probably be necessary where: (1) "therapeutic effect is indirect"; (2) "irreversible toxicity can occur"; (3) "peak to trough differences of the immediate release form are very large"; or (4) "there is any other reasonable uncertainty concerning the relationship between plasma concentration and therapeutic and adverse effects." For a controlled release oral dosage form of a marketed immediate release drug for which an extensive base of pharmacodynamic-pharmacokinetic data exist, the report identifies two types of pharmacokinetic studies that may constitute the sole basis for approval: (a) single dose, three-way crossover with three treatment regimens; and (b) multiple dose steady-state studies.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS010676

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel